Literature DB >> 22709347

Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.

Dipanjan Pan1, Nibedita Sanyal, Anne H Schmieder, Angana Senpan, Benjamin Kim, Xiaoxia Yang, Grace Hu, John S Allen, Richard W Gross, Samuel A Wickline, Gregory M Lanza.   

Abstract

BACKGROUND: The chemical instability of antiangiogenic fumagillin, combined with its poor retention during intravascular transit, requires an innovative solution for clinical translation. We hypothesized that an Sn-2 lipase-labile fumagillin prodrug, in combination with a contact-facilitated drug delivery mechanism, could be used to address these problems.
METHODS: α(v)β(3)-targeted and nontargeted nanoparticles with and without fumagillin in the prodrug or native forms were evaluated in vitro and in vivo in the Matrigel™ (BD Biosciences, CA, USA) plug model of angiogenesis in mice.
RESULTS: In vitro experiments demonstrated that the new fumagillin prodrug decreased viability at least as efficacious as the parent compound, on an equimolar basis. In the Matrigel mouse angiogenesis model, α(v)β(3)-fumagillin prodrug decreased angiogenesis as measured by MRI (3T), while the neovasculature was unaffected with the control nanoparticles.
CONCLUSION: The present approach resolved the previously intractable problems of drug instability and premature release in transit to target sites.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22709347      PMCID: PMC3498609          DOI: 10.2217/nnm.12.27

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  39 in total

1.  Secreted phospholipase A(2) as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue.

Authors:  Jesper Davidsen; Kent Jørgensen; Thomas L Andresen; Ole G Mouritsen
Journal:  Biochim Biophys Acta       Date:  2003-01-10

2.  Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.

Authors:  Hui-Fang Zhou; Grace Hu; Samuel A Wickline; Gregory M Lanza; Christine T N Pham
Journal:  Nanomedicine (Lond)       Date:  2010-09       Impact factor: 5.307

3.  Angiogenesis and inflammation face off.

Authors:  Beat A Imhof; Michel Aurrand-Lions
Journal:  Nat Med       Date:  2006-02       Impact factor: 53.440

4.  Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.

Authors:  E C Griffith; Z Su; S Niwayama; C A Ramsay; Y H Chang; J O Liu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470.

Authors:  A P Kudelka; C F Verschraegen; E Loyer
Journal:  N Engl J Med       Date:  1998-04-02       Impact factor: 91.245

Review 6.  TNP-470 (AGM-1470): mechanisms of action and early clinical development.

Authors:  V Castronovo; D Belotti
Journal:  Eur J Cancer       Date:  1996-12       Impact factor: 9.162

7.  Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases.

Authors:  J Wang; P Lou; J Henkin
Journal:  J Cell Biochem       Date:  2000-04       Impact factor: 4.429

8.  Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes.

Authors:  S M Arfin; R L Kendall; L Hall; L H Weaver; A E Stewart; B W Matthews; R A Bradshaw
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugs.

Authors:  Thomas L Andresen; Jesper Davidsen; Mikael Begtrup; Ole G Mouritsen; Kent Jørgensen
Journal:  J Med Chem       Date:  2004-03-25       Impact factor: 7.446

10.  Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470.

Authors:  R Offodile; T Walton; M Lee; A Stiles; M Nguyen
Journal:  Tumori       Date:  1999 Jan-Feb
View more
  12 in total

Review 1.  Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy.

Authors:  Junjie Chen; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Adv Chronic Kidney Dis       Date:  2013-11       Impact factor: 3.620

2.  Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Authors:  Alison K Esser; Anne H Schmieder; Michael H Ross; Jingyu Xiang; Xinming Su; Grace Cui; Huiying Zhang; Xiaoxia Yang; John S Allen; Todd Williams; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Katherine N Weilbaecher
Journal:  Nanomedicine       Date:  2015-10-27       Impact factor: 5.307

3.  Angiogenesis and airway reactivity in asthmatic Brown Norway rats.

Authors:  Elizabeth M Wagner; John Jenkins; Anne Schmieder; Lindsey Eldridge; Qiong Zhang; Aigul Moldobaeva; Huiying Zhang; John S Allen; Xiaoxia Yang; Wayne Mitzner; Jochen Keupp; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza
Journal:  Angiogenesis       Date:  2014-08-23       Impact factor: 9.596

4.  A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.

Authors:  Dipanjan Pan; Benjamin Kim; Grace Hu; Deepti Sood Gupta; Angana Senpan; Xiaoxia Yang; Anne Schmieder; Corban Swain; Samuel A Wickline; Michael H Tomasson; Gregory M Lanza
Journal:  Nanomedicine (Lond)       Date:  2015-01       Impact factor: 5.307

5.  Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.

Authors:  Hui-Fang Zhou; Huimin Yan; Angana Senpan; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Christine T N Pham
Journal:  Biomaterials       Date:  2012-08-24       Impact factor: 12.479

6.  Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.

Authors:  Deepti Soodgupta; Dipanjan Pan; Grace Cui; Angana Senpan; Xiaoxia Yang; Lan Lu; Katherine N Weilbaecher; Edward V Prochownik; Gregory M Lanza; Michael H Tomasson
Journal:  Mol Cancer Ther       Date:  2015-03-30       Impact factor: 6.261

7.  alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.

Authors:  Ruiying Zhang; Dipanjan Pan; Xin Cai; Xiaoxia Yang; Angana Senpan; John S Allen; Gregory M Lanza; Lihong V Wang
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

Review 8.  Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Authors:  Dipanjan Pan; Christine T N Pham; Katherine N Weilbaecher; Michael H Tomasson; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-08-21

9.  Anti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat.

Authors:  Gregory M Lanza; John Jenkins; Anne H Schmieder; Aigul Moldobaeva; Grace Cui; Huiying Zhang; Xiaoxia Yang; Qiong Zhong; Jochen Keupp; Ismail Sergin; Krishna S Paranandi; Lindsey Eldridge; John S Allen; Todd Williams; Michael J Scott; Babak Razani; Elizabeth M Wagner
Journal:  Theranostics       Date:  2017-01-01       Impact factor: 11.556

10.  Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.

Authors:  Hui-fang Zhou; Huimin Yan; Ying Hu; Luke E Springer; Xiaoxia Yang; Samuel A Wickline; Dipanjan Pan; Gregory M Lanza; Christine T N Pham
Journal:  ACS Nano       Date:  2014-06-24       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.